December 2014: We added three new posters highlighting our stable amyloid beta 1-42 oligomers to the publications section.
July 2014: Crossbeta BV CEO Guus Scheefhals explains about how we fight protein misfolding diseases such as Alzheimer's and Parkinson's (in Dutch). The program was aired on RTL4 on July 12 2014.
Stabilizing oligomers and targeting toxic oligomers is the basis for Crossbeta's oligomer drug discovery platforms which are accessible for partnering in therapeutic areas such as Alzheimer's, Parkinson's, Huntington and Diabetes Type 2.
In our Alzheimer program we have recently completed a high throughput screening campaign with 100,000 compounds resulting in the selection of 5 hit classes with >50% neutralizing effect on oligomer-induced neurotoxicity.
Stable oligomers can also be used as reference in biomarker assays.